Bioventus Inc. (NASDAQ:BVS) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Bioventus received a “Moderate Buy” consensus rating from six analysts, with five buys and one hold. The average 12-month price target is $16.80, above the stock’s reported price of $13.81.
• For its latest quarter, Bioventus reported adjusted EPS of $0.22, matching estimates, and revenue of $153.21 million. The company issued fiscal 2026 EPS guidance of $0.75–$0.79.
• Institutional investors and hedge funds own 62.94% of Bioventus shares, with several firms recently increasing stakes or initiating new positions.

Bioventus Inc. (NASDAQ:BVS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $16.80.

BVS has been the topic of several research reports. Barrington Research set a $18.00 price target on Bioventus in a research note on Thursday, August 6th. Canaccord Genuity Group lifted their price objective on Bioventus from $15.00 to $19.00 and gave the stock a "buy" rating in a report on Monday, August 17th. Cantor Fitzgerald restated an "overweight" rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, August 17th. Craig Hallum restated a "buy" rating and issued a $18.00 target price on shares of Bioventus in a research note on Thursday, August 6th. Finally, Weiss Ratings raised Bioventus from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, August 6th.

Bioventus Stock Performance

NASDAQ BVS opened at $13.81 on Monday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.69 and a quick ratio of 1.17. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 17.94, a P/E/G ratio of 1.76 and a beta of 0.65. The company's fifty day moving average is $13.51 and its two-hundred day moving average is $11.04. Bioventus has a 52-week low of $6.26 and a 52-week high of $15.89.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The company had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts forecast that Bioventus will post 0.79 EPS for the current year.

Institutional Trading of Bioventus

Several institutional investors have recently made changes to their positions in BVS. Squarepoint Ops LLC increased its stake in Bioventus by 21.9% in the second quarter. Squarepoint Ops LLC now owns 269,267 shares of the company's stock valued at $2,542,000 after acquiring an additional 48,414 shares during the period. Globeflex Capital L P acquired a new stake in Bioventus during the second quarter valued at approximately $1,566,000. Bank of New York Mellon Corp bought a new stake in shares of Bioventus in the 2nd quarter valued at approximately $1,438,000. Bank of America Corp DE grew its stake in shares of Bioventus by 40.3% in the 1st quarter. Bank of America Corp DE now owns 86,057 shares of the company's stock valued at $786,000 after purchasing an additional 24,723 shares during the period. Finally, Engine Capital Management LP acquired a new position in shares of Bioventus in the 1st quarter worth approximately $2,876,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

About Bioventus

Bioventus Inc NASDAQ: BVS is a medical device and biologics company focused on products that support healing and improve function for patients with musculoskeletal conditions. Its portfolio is designed for use in orthopedics, sports medicine, rehabilitation and related specialties.

The company's products include bone-healing systems, such as EXOGEN, which uses ultrasound technology to support fracture healing, as well as osteoarthritis treatments including injectable hyaluronic acid products such as DUROLANE and GELSYN-3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.